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ASPP1 and ASPP2 bind active RAS, potentiate RAS
signalling and enhance p53 activity in cancer cells
Y Wang1,2, N Godin-Heymann1,2,3, X Dan Wang1,2,4, D Bergamaschi1,5, S Llanos1 and X Lu*1
RAS mutations occur frequently in human cancer and activated RAS signalling contributes to tumour development and
progression. Apart from its oncogenic effects on cell growth, active RAS has tumour-suppressive functions via its ability to
induce cellular senescence and apoptosis. RAS is known to induce p53-dependent cell cycle arrest, yet its effect on p53-
dependent apoptosis remains unclear. We report here that apoptosis-stimulating protein of p53 (ASPP) 1 and 2, two activators of
p53, preferentially bind active RAS via their N-terminal RAS-association domains (RAD). Additionally, ASPP2 colocalises with
and contributes to RAS cellular membrane localisation and potentiates RAS signalling. In cancer cells, ASPP1 and ASPP2
cooperate with oncogenic RAS to enhance the transcription and apoptotic function of p53. Thus, loss of ASPP1 and ASPP2 in
human cancer cells may contribute to the full transforming property of RAS oncogene.
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The evolutionarily conserved RAS proto-oncogenes encode
21 kDa guanine nucleotide-binding proteins. RAS–GDP is
inactive, whereas RAS–GTP is active and binds effectors to
activate RAS/RAF/ERK or RAS/PI3K/AKT signalling cas-
cades that are important in cell growth and death.1,2 RAS
activation takes place primarily at the plasma membrane. As
one of the first oncogene identified in human cancer,
activation of mutations at residues 12, 13 or 61 result in a
mutant RAS that constitutively binds GTP. Activation of RAS
can also be achieved by overexpression or mutation of its
upstream activators such as epidermal growth factor receptor
(EGFR).3,4 Apart from its oncogenic effect, it is emerging that
RAS also has tumour-suppressive functions through its ability
to induce senescence and apoptosis.5 The final outcome of
these contradictory signals depends largely on the cell type
and context. It is therefore important to identify molecules that
dictate cellular response to RAS activation.
Oncogenes, such as RAS, Myc and E1A are also known to
activate the tumour-suppressor p53 via their ability to induce
the expression of Arf and prevent Mdm2-mediated protein
degradation of p53.6–8 Oncogenic signalling to p53 leads to
one of two responses: cell cycle arrest or apoptosis.
Oncogenic RAS induces senescence mediated by p53 and
its downstream target gene p21.9–11 However, the tumour-
suppressive function of p53 is closely linked to its ability to
induce apoptosis. Therefore, it remains unclear whether
oncogenic RAS has a role in regulating p53-mediated
apoptosis.
Consistent with p53 as an important mediator of oncogenic
RAS-induced senescence in primary fibroblasts, mutations of
p53 and RAS are found at high frequency in colorectal and
pancreatic tumours. In colorectal cancer, RAS mutations are
an early event, whereas p53mutations occur predominantly in
metastatic tumours.12 Therefore, there might be a selective
advantage in tumours expressing oncogenic RAS to inacti-
vate the tumour-suppression function of p53. Regulators of
p53 may thus also have a role in affecting cellular responses
to RAS. Among those, apoptosis-stimulating protein of p53
(ASPP)1 and ASPP2 are two such potential candidates.
ASPP1 and ASPP2 belong to the evolutionarily conserved
ASPP family of proteins, including ASPP1, ASPP2 and
iASPP, which contain signature sequences in their C-termini;
ankyrin repeats, a SH3 domain and proline-rich sequences.
The evolutionarily conserved RAS-association domains
(RAD) of ASPP1 and ASPP2 are located at their N-termini
(first 100 amino acids) and this sequence does not exist in
iASPP’s N-terminus. In mouse primary fibroblasts, ASPP2 is a
key mediator of RAS-induced senescence via its ability to
inhibit RAS-induced autophagy, and nuclear accumulation of
small ubiquitin-like modifier (SUMO) modified cyclin D1.13,14
Mechanistically, the N-terminus of ASPP2 binds ATG5 and
inhibits RAS-induced autophagy, independently of p53.13
In addition to inducing cellular senescence in primary cells,
RAS activation induces apoptosis in certain cancer cells.
Similarly, DNA damage- or oncogene-induced p53 mainly
induces senescence in primary cells, but apoptosis in cancer
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cells. One explanation for this selective action of p53 in
different cell types is the expression levels and activities of the
ASPP family of proteins. In cancer cells, ASPP1 and ASPP2
stimulate, whereas iASPP inhibits, apoptosis induced by p53
and its family members, p63 and p73.15–18 ASPP1 and
ASPP2 are also transcriptional targets of E2F, and elevated
E2F activity mainly occurs in cancer cells due to inactivation of
the Rb pathway. Moreover, E2F1 binds and cooperates with
p53 to induce apoptosis.19 Therefore, in cancer cells,
enhanced activities of E2F, ASPP1 and ASPP2 may sensitise
cancer cells to p53-induced apoptosis.19,20 Importantly, the
ability of ASPP1 and ASPP2 to stimulate p53-dependent
apoptosis in cancer cells also requires their first 120 amino
acids, as mutants lacking them are unable to coactivate with
p53, even though they interact with p53.16
Recently, ASPP2 was shown to bind and colocalise with
PAR3 via its N-terminus to maintain the integrity of cell polarity
and adherence junctions.21,22 RAS activation mainly occurs at
the cellular membrane, and the RAD-containing N-terminus of
ASPP2 is crucial in mediating oncogenic RAS-induced
senescence in primary fibroblasts. Therefore, it is possible
that ASPP1 and ASPP2 may interact with RAS and regulate
RAS signalling. As a result, the status of ASPP1 and ASPP2
may dictate the cellular response to RAS signalling in both
primary fibroblasts and cancer cells. Here we show that
ASPP1 and ASPP2 bind active RAS. Endogenous ASPP2
contributes to endogenous RAS cellular membrane localisa-
tion, and potentiates RAS signalling. Additionally, we demon-
strate that ASPP1 and ASPP2 cooperate with oncogenic RAS
to enhance the transcription and apoptotic function of p53 in
cancer cells.
Results
ASPP1 and ASPP2 preferentially bind active RAS. The
evolutionarily conserved N-terminal 100 amino acids of
ASPP1 and ASPP2 share high sequence homology with
RAD present in c-Raf, PI3K and RasGDL,23 suggesting that
ASPP1 and ASPP2 may interact with RAS. Purified
N-terminal ASPP1 and purified RAS loaded with [3H]-labelled
GTP or GDP were used to investigate whether ASPP1 RAD
has a binding preference towards either RAS–GTP or RAS–
GDP. We observed that purified ASPP1 fragment (1–310),
containing the RAD, interacted with purified RAS in vitro. The
ASPP1 N-terminus bound RAS–GTP with a four-fold higher
affinity than RAS–GDP (Figure 1a, compare lanes 4 and 5).
To illustrate that only the N-terminal region of ASPP1 binds
RAS, various truncated ASPP1 mutants were constructed.
All truncated ASPP1 mutants containing RAD complexed
with endogenous RAS except ASPP1 (310–1090) lacking
RAD (Supplementary Figures 1a and b).
Activated RAS has a higher interaction affinity with the
RAS-binding domain (RBD) of Raf1. Agarose beads linked to
the Raf1–RBD can be used to pull down proteins associated
with RAS–GTP. In this assay, the presence of small but
detectable amounts of c-Raf served as a positive control for
the assay. We thus used this as an alternative assay to
investigate whether ASPP2 also selectively binds RAS–GTP.
Under the same conditions, the percentage of ASPP2 pulled
down by Raf1–RBD is clearly higher than that of c-Raf,
illustrating that endogenous ASPP2 also complexes with
active RAS (Figure 1b). Raf1–RBD failed to pull down iASPP,
which does not contain RAD at its N-terminus. These results
illustrate that ASPP1 and ASPP2 can bind active RAS, and
this interaction is likely mediated through their N-termini.
An ASPP2 inducible U2OS cell line that expresses
wild-type p53 was first used to test whether endogenous
wild-type RAS binds ASPP2 with different efficiency upon
EGF stimulation. Endogenous RAS was immunoprecipitated
with or without ASPP2 induction in the presence or absence
of EGF treatment (Supplementary Figure 1c). We found
that there is very little binding between RAS and ASPP2 in
starved cells. The RAS–ASPP2 complex was mainly detected
in EGF-treated cells that express active RAS (Supplementary
Figure 1c, compare lanes 7 and 8). It is important to note that
the expression levels of RAS and ASPP2 are similar in cells
before or after EGF treatment. Moreover, an interaction was
also observed between endogenous ASPP2 and HRASV12 in
a human colon cancer cell line HKe3 ER:HRASV12 cells, in
which RAS activation is induced upon the addition of 4-
hydroxytamoxifen (4-OHT) (Figure 1c).24,25 The ability of
endogenous ASPP2 to bind with endogenous active RAS was
further tested in mouse embryonic fibroblasts (MEFs) derived
from ASPP2 wild-type and ASPP2(D3/D3) embryos. Growth
factors such as EGF or insulin were used to stimulate serum-
starved ASPP2(þ /þ ) and ASPP2(D3/D3) MEFs to induce RAS
activation. Endogenous ASPP2 and RAS were co-immuno-
precipitated with an anti-RAS antibody in ASPP2(þ /þ ) MEFs.
However, no co-immunoprecipitation was detected in
ASPP2(D3/D3) MEFs, which occasionally express reduced
amounts of N-terminal-truncated ASPP2 (Figure 1d). These
data demonstrate that ASPP2 preferentially binds RAS when
it is activated.
To provide further evidence that ASPP1 and ASPP2
preferentially interact with RAS–GTP, a p53-null osteosar-
coma cell line Saos2 was starved for 20 h and then stimulated
with 20% foetal calf serum (FCS) and EGF. More RAS was
detected in the ASPP1 and ASPP2 immunoprecipitates
derived from serum- and EGF-stimulated cell lysates than in
non-stimulated ones (Figure 1e, compare lanes 1–2 for
ASPP2 and 3–4 for ASPP1). All these suggest that N-termini
of ASPP1 and ASPP2 selectively bind active RAS. This new
property of ASPP1 and ASPP2 is independent of p53 because
p53 binds the C-termini of the ASPPs and Saos2 cells are
p53-null.
ASPP2 colocalises with and contributes to RAS activa-
tion at cell membrane. Activated RAS is mainly located at
cellular membranes. To test the biological importance of the
observed RAS–ASPP interactions, we first examined the
cellular localisation of exogenously coexpressed HRASV12
and ASPP2, and observed that they colocalise to the cell
membrane in U2OS cells (Figure 2a). In HK-e3ER:HRASV12
cells, ASPP2 is normally expressed at cell/cell junctions.22
One hour after RAS induction, endogenous ASPP2 coloca-
lised with induced HRASV12 at the cell membrane in
HKe3 cells (Figure 2b). Importantly, ASPP2 depletion by
RNA interference (RNAi) largely abolished the membrane
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localisation of HRASV12 after RAS induction in these cells
(Supplementary Figure 2).
The ability of endogenous ASPP2 to bind and colocalise
with endogenous active RAS was tested in a physiological
setting. In ASPP2(þ /þ ) MEFs, insulin-induced active RAS
and ASPP2 colocalised at the cell membrane. The majority of
the cells expressing membrane-associated ASPP2 also had
membrane-localised RAS and vice versa (Figure 2c, left panel
with arrows). RAS was not detected at the cell membrane in
ASPP2(D3/D3) MEFs (Figure 2c) under the same conditions,
consistent with the results in HKe3 cells (Supplementary
Figure 2). Similar results were observed in HRASV12-
expressing ASPP2(þ /þ ) and ASPP2(D3/D3) MEFs (Figure 2c,
right panel). Together, these data suggest that ASPP2
colocalises with RAS and facilitates the membrane localisa-
tion of RAS in human cancer cells and MEFs.
ASPP2’s N-terminus is required and sufficient to
potentiate RAS signalling. The biological implications of
ASPP2–RAS binding and colocalisation were investigated by
examining the RAS signalling cascade in ASPP2(þ /þ ) and
ASPP2(D3/D3) MEFs. The basal phosphorylation level of ERK
in ASPP2(þ /þ ) MEFs was higher than that in ASPP2(D3/D3)
MEFs (Figure 3a; Supplementary Figure 3a). This difference
was more notable in HRASV12-expressing ASPP2(þ /þ ) than
in ASPP2(D3/D3) MEFs (Figure 3b; Supplementary Figure 3b).
Figure 1 ASPP1 and ASPP2 preferentially bind active RAS. (a) ASPP1’s N-terminus preferentially binds RAS–GTP in vitro. RAS protein, loaded with either tritium-
labelled GDP or GTP, was added to V5-tagged recombinant ASPP1 (1–310) and immunoprecipitated with V5 antibody. As a negative control, RAS.GDP and RAS–GTP were
immunoprecipitated with V5 antibody in the absence of ASPP1 (1–310). Co-immunoprecipitated RAS was quantified according to the presence of 3H-GTP or 3H-GDP. Values
are shown as a bar graph. Standard deviation represents the mean of three independent experiments. (b) ASPP2 binds activated RAS in HKe3 cells. HKe3 ER:HRASV12
cells were treated with 100 nM 4-OHT for 2 days and Raf-1–RBD agarose pull-down assays were performed to pull down GTP-bound active RAS. (c) ASPP2 binds activated
ER:HRASV12. Total cell lysates from HKe3 ER:HRASV12 cells treated with or without 4-OHT were immunoprecipitated with an anti-ASPP2 antibody, or control IgG as
indicated. (d) ASPP2 binds activated RAS in MEFs. Total cell lysates from ASPP2(þ /þ ) or ASPP2(D3/D3) MEFs treated with EGF (20 ng/ml) or insulin (1 mg/ml) for 15 min were
immunoprecipitated with an anti-HRAS antibody or control IgG. (e) Saos2 cells were either starved in 0.5%, or stimulated with 20%, FCS plus 20 ng/ml EGF overnight. Lysates
were collected and immunoprecipitated with rabbit anti-ASPP1 (ASPP1.88) or anti-ASPP2 (ASPP2/77) antibodies, respectively. The ASPP proteins were detected with
mAbASPP1.54.1, which is known to crossreact with both ASPP1 and ASPP2
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Upon insulin treatment, a stronger response was observed in
ASPP2(þ /þ ) compared with ASPP2(D3/D3) MEFs, reflected
by the phosphorylation level of both ERK and AKT (Figures
3a and b; Supplementary Figures 3a and b). These data
suggest that by binding to and colocalising with active RAS at
the cell membrane, ASPP2 potentiates RAS signalling.
The effects of ASPP2 on RAS signalling were further
confirmed with human phospho-MAPK arrays. As expected,
phosphorylation levels of several downstream effectors of
RAS were increased to various extents following RAS
activation in HKe3 ER:HRASV12 cells. ASPP2 knockdown
dampened the RAS-induced activation of some effectors such
as MSK2, p38s and JNKs (Supplementary Figure 3d).
Consistent with this, RAS-induced phosphorylation of ERK
and AKT is compromised in these cells upon ASPP2 depletion
(Figure 3c; Supplementary Figure 3c).
Finally, to confirm whether the RAD in the N-terminus of
ASPP2 is critical for its potentiation of RAS signalling, two
ASPP2 mutants were generated: ASPP2 (1–360) and ASPP2
(123–1128), representing a naturally occurring ASPP2 splice
Figure 2 ASPP2 colocalises with and contributes to RAS activation at the cell membrane. (a) U2OS cells co-transfected with ASPP2 (red) and HRASV12 (green) show
colocalisation of both at the cell membrane (yellow). (b) Immunofluorescence staining of HRAS in HKe3 ER:HRASV12 cells transfected with control or ASPP2 siRNA for
3 days, followed by treatment without (control) or with 100 nM 4-OHT for 1 h. Arrows indicate cell membrane. (c) Immunofluorescence staining of ASPP2 or HRAS in
ASPP2(þ /þ ) or ASPP2(D3/D3) MEFs, with or without HRASV12 expression, before or after treatment as indicated. Cells were treated with 1mg/ml insulin for 15 min. Arrows
indicate cell membrane
ASPP1/2 in RAS signalling and apoptosis
Y Wang et al
528
Cell Death and Differentiation
variant.26 Retroviruses expressing full-length or truncated
ASPP2 were infected into HRASV12-expressing ASPP2(D3/D3)
MEFs. The impaired RAS–ERK and RAS–AKT signalling in
HRASV12-expressing ASPP2(D3/D3) MEFs was largely
rescued by the expression of full-length ASPP2 (Figure 3d,
lower panel, lanes 7–9). The expression of ASPP2 (1–360) also
partially restored the activities of ERK and AKT (Figure 3d,
lower panel, lanes 10–12). This may be explained by the
reduced expression of ASPP2 (1–360) relative to full-length
ASPP2 (Figure 3e). The expression of ASPP2 (123–1128)
failed to stimulate ERK and AKT pathways, although the
amount of protein was similar to that of ASPP2 (1–1128)
(Figure 3d (lower panel, lanes 13–15) and Figure 3e). This
result illustrates that the N-terminus of ASPP2 (1–123) is
sufficient to potentiate RAS signalling.
ASPP1 and ASPP2 cooperate with RAS to enhance
the transcriptional activity of p53. We showed previously
that the N-termini of ASPP1 and ASPP2 are required for full
enhancement of p53 activity.16 We thus tested whether
ASPP1 and ASPP2 cooperate with RAS to stimulate the
apoptotic function of p53. HRASV12 or KRASV12 was co-
transfected with ASPP1, ASPP2 and p53 into Saos2 cells.
The results shown in Figure 4a illustrate that HRASV12 or
KRASV12 alone had a small stimulatory effect on p53
transactivity. As expected, coexpression of ASPP1 or
ASPP2 with p53 enhanced the transcriptional activity of
p53 on the Bax promoter–luciferase reporter by 3 and 10
times, respectively. In the presence of ASPP1, expression of
HRASV12 or KRASV12 stimulated the transactivation func-
tion of p53 by B10-fold (Figure 4a). Similarly, the
coexpression of ASPP2 and HRASV12 or KRASV12
stimulated the transcriptional activity of p53 by around
30–35-fold. When the transcriptional activities of p53þ
ASPP1 and p53þASPP2 were set as 1, we observed that
both HRASV12 and KRASV12 were able to further enhance
the transcriptional activity of p53 by around three-folds
(Figure 4b).
Figure 3 ASPP2’s N-terminus is required and is sufficient to potentiate RAS signalling. (a and b) ASPP2(þ /þ ) or ASPP2(D3/D3) MEFs, in the absence (a), or presence of
HRASV12 (b) were serum-starved overnight, followed by stimulation with 1 mg/ml insulin for the indicated times. The activation status of ERK or AKT was determined by
western blots. (c) Western blots showing the expression levels of endogenous ASPP2, phosphorylated ERK, ERK, phosphorylated AKT, AKT, phosphorylated S6 and S6 in
HKe3 ER:HRASV12 cells with indicated treatments. GAPDH was used as a loading control. (d) Oncogenic HRASV12-expressing ASPP2(þ /þ ) or ASPP2(D3/D3) MEFs
infected with retroviruses expressing full-length ASPP2 or truncated mutants were serum-starved overnight before stimulation with 1mg/ml insulin for the indicated times. The
activation status of ERK or AKT was determined by western blot analysis. (e) Western blots showing expression levels of full-length ASPP2 and its mutants in HRASV12-
expressing ASPP2(D3/D3) MEFs as indicated
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To demonstrate further that RAS activation is required to
enhance the transcriptional activity of p53 via ASPP1 or
ASPP2, a wild-type RAS or a dominant negative form of
HRAS–HRASN17 was co-transfected with ASPP2 and p53
into Saos2 cells. The results shown in Figure 4c illustrate
that HRASV12 alone had a small stimulatory effect on the
transactivation function of p53. In the presence of ASPP2,
however, HRASV12 stimulated the transactivation function
of p53 by approximately 3-fold. When HRASN17 was
co-transfected with ASPP2 and p53, the transactivation
activity of p53 was inhibited. This inhibition was via ASPP2,
as HRASN17 transfected only with p53 did not have such
a strong inhibitory effect: HRASN17 inhibited p53 and
ASPP2 activity more than 4-fold, whereas it inhibited p53 via
endogenous ASPP about 1.5-fold. In contrast, wild-type RAS
had very little effect on the transactivation function of p53. This
may be explained by the fact that increased RAS expression
does not necessarily lead to increased levels of RAS–GTP in
cells.
We tested whether the observed ability ofRAS oncogene to
cooperate with ASPP2 to enhance p53 transcriptional activity
is promoter-specific. Three p53 target gene promoter-contain-
ing reporters, PIG3-, Bax- and Mdm2-luciferases, were used.
We observed that HRASV12 had the most profound effect on
the transcriptional activity of p53 on PIG3 and BAX promoters.
Under the same conditions, a reduced stimulatory effect was
seen on Mdm2 promoter (Figure 4d). This agrees with our
previous finding that ASPP2 has minimal impact on the
transcriptional activity of p53 on the promoters of Mdm2
and p21waf1.16 Consistent with this, we also observed that
p21waf1 mRNA expression induced by activated RAS in HKe3
cells is independent of ASPP2 status, as ASPP2 knockdown
in these cells did not alter p21waf1 expression (Supplementary
Figure 4a).
Figure 4 ASPP1 and ASPP2 cooperates with RAS to enhance the transcriptional activity of p53. (a) Saos2 cells were transfected as indicated with a Bax–luciferase
reporter and the luciferase activity shown (lower left panel). The expression of the proteins was verified by western blot (upper left panel). (b) The value of ASPP1þ p53 or
ASPP2þ p53 were taken as 1.0 to reflect the fold increase of ASPP1/ASPP2 and p53 in the presence of mutant RAS. The mean values were derived from three independent
experiments. (c) Saos2 cells were transfected with a Bax–luciferase reporter, p53, wild-type or mutant RAS, in the presence or absence of ASPP2 as indicated. The value of
ASPP2þ p53 was taken as 1.0 to reflect the fold increase. The mean values were derived from three independent experiments. (d) Saos2 cells were transfected as indicated
with a Bax–luciferase or PIG3–luciferase or Mdm2–luciferase reporter; luciferase activity is reported here. (e) Saos2 cells were co-transfected with the p53 reporter Bax–
luciferase, p53, ASPP2, HRAS shRNA or KRAS shRNA, as indicated
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The requirement of endogenous RAS to stimulate the
transcriptional activity of p53 via ASPP2 was tested using
shRNA against HRAS or KRAS. Their ability to specifically
reduce the expression level of HRAS or KRAS was confirmed
(Supplementary Figure 4b). We found that RNAi against
HRAS or KRAS dampened the ability of ASPP2 to stimulate
the transactivation function of p53 on the promoters of the pro-
apoptotic gene Bax (Figure 4e) and PIG3 (Supplementary
Figure 4c). All these support the notion that ASPP1 and
ASPP2 cooperate with RAS to enhance the transcriptional
activity of p53 for apoptotic genes. This cooperation is likely to
be mediated by the identified interaction between active RAS
and RAD of the ASPPs, which also explains why the RAD of
the ASPPs is required for their full potential to enhance the
transcriptional activity of p53.
RAS oncogene enhances the apoptotic function of p53
via ASPP1 and ASPP2. The requirement of RAS activation
to potentiate the pro-apoptotic function of ASPP1 and ASPP2
was tested in two human cancer cell lines with wild-type
p53: MCF7 and U2OS. As published previously, increased
expression of ASPP1 or ASPP2 induces p53-mediated
apoptosis in both cell lines.16 Using shRNAs to reduce the
expression of endogenous HRAS or KRAS, we observed a
reduction in the percentage of apoptosis in cells induced by
ASPP1 or ASPP2 overexpression (Figure 5a). These
findings suggest that endogenous HRAS and KRAS are
required for the full activities of ASPP1 and ASPP2.
To further confirm this, we used HKe3 ER:HRASV12 cells,
in which RAS activation is induced upon the addition of 4-
OHT. Importantly, oncogenic RAS activation induced apop-
tosis in these cells indicated by the presence of cleaved-
PARP (Figure 5c). To test whether p53 has a role in mediating
the observed RAS-induced apoptosis in HKe3 cells, RNAi
against p53 was used. Depletion of p53 abolished RAS-
induced apoptosis in these cells. This is evident from a lack of
PARP cleavage in these cells (Figure 5d).
RAS activation induces ASPP2 translocation and
enhances p53 binding in colon cancer cells. To under-
stand how ASPP2 cooperates with p53 to induce apoptosis in
cancer cells, we examined the cellular localisation of ASPP2 in
HKe3 ER:HRASV12 cells upon RAS induction. We observed
that endogenous ASPP2 translocates from cell/cell junctions to
the cytosol/nucleus following RAS activation (Figure 6a). This is
also confirmed by the detection of an increase in the expression
levels of ASPP2 in the nuclear and cytoplasmic fractions in
these cells upon RAS activation, with around two–three-folds
increase in the level of nuclear and cytoplasmic ASPP2,
respectively (Figure 6b). Moreover, we also detected an
increase in the amount of p53–ASPP2 complex in these cells
following RAS activation (Figure 6c). To test whether endo-
genous ASPP2 mediates the observed RAS-induced apoptosis
in HKe3 cells, ASPP2 RNAi was used. ASPP2 knockdown
abolished RAS-induced apoptosis indicated by a lack of PARP
cleavage (Figure 6d). These data identify ASPP2 as an
important mediator of oncogenic RAS-induced apoptosis. This
may be achieved via the ability of the active RAS to induce the
cellular translocation of ASPP2, and enhance the ability of
ASPP2 to bind p53 and to enhance its activity.
Discussion
In addition to its well-established oncogenic properties, it is
emerging that RAS also has growth-suppressive functions by
its ability to induce senescence in primary fibroblasts and
apoptosis in cancer cells. Recently, we showed that ASPP2 is
a potent mediator of RAS-induced senescence. This property
is p53-independent, and is achieved partly through the ability
of the N-terminus of ASPP2 to bind ATG5 and to inhibit RAS-
induced autophagy, as elevated autophagy activity bypasses
oncogenic RAS-induced senescence in fibroblasts.13
We show here that ASPP1 and ASPP2 bind active RAS via
their N-termini. ASPP2 potentiates RAS signalling and
activates RAS at the cellular membrane. Moreover, the
observed RAS–ASPP interactions enhance the transcription
and apoptotic function of p53 in cancer cells. In primary
fibroblasts, ASPP2 mediates RAS-induced senescence inde-
pendent of p53, whereas in cancer cells, ASPP1 and ASPP2
mediate RAS-induced p53-dependent apoptosis. Therefore,
ASPP1 and ASPP2 are the key mediators of RAS signalling in
both primary and cancer cells. The status of ASPP1 and
ASPP2 may therefore dictate the cellular response to RAS
signalling. Therefore, the ability of ASPP2 to be located at cell
junctions to bind and colocalise with RAS on the one hand,
and located in the cytoplasm and bind p53 upon RAS
activation on the other, places ASPP2 in an ideal position to
survey the intensity of RAS signalling and to coordinate
appropriate cellular responses accordingly. One possible
explanation for this property of ASPP2 is that, when RAS is
activated, it binds active RAS and controls the intensity of the
RAS signal. When RAS signalling is elevated to a certain
level, high enough to disrupt cell/cell junctions for example, it
may then displace ASPP2 from cell/cell junctions. This
redistribution of ASPP2 would thus enable the interaction
with ATG5 to inhibit autophagy and to mediate RAS-induced
senescence or to bind p53 to promote apoptosis (Figure 6e).
As the levels of RAS activation induced by growth factors such
as EGF or insulin in primary cells in normal growth conditions
is lower than that in cancer cells caused by mutation or
amplifications ofRAS orEGFR genes, this cellular localisation
of ASPP2 and its binding partners may differ between primary
cells and cancer cells. Future studies are needed to test
whether cellular localisation of ASPP1 and ASPP2, and their
ability to interact with ATG5 or p53 may be an underline
reason for why RAS or p53 activation predominately induces
senescence in primary cells but apoptosis in cancer cells.
Although ASPP1 and ASPP2 share sequence similarity and
have many overlapping functions in vitro, including the
interaction with active RAS, they have distinct biological
functions in vivo. ASPP2 binds PAR3 and locates at cell/cell
junctions,21,22 whereas ASPP1 binds YAP and locates in
cytosol.27,28 ASPP1 deficiency in mice is predominantly
tolerated in mouse development, although lymphatic vessel
leakage occurs.29 This differs from ASPP2-deficient mice,
where a loss of cell polarity and excessive proliferation of
neural progenitors are common features. Importantly, ASPP2
heterozygosity is sufficient to predispose mice to develop
tumours,30,31 establishing ASPP2’s tumour-suppressive func-
tion. These differences may explain why ASPP2 depletion
alone is sufficient to affect RAS signalling. Future studies are
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therefore needed to elucidate which of the in vivo functions of
ASPP1 are influenced by the identified ASPP1–RAS
interaction.
There have been many reports demonstrating that RAS
activation inhibits apoptosis and promotes survival. Para-
doxically, increasing numbers of studies have also shown that
RAS activation induces apoptosis. The effect of RAS on
survival versus apoptosis depends largely on cell types and
concurrent activation of other signalling pathways. The most
prominent pathway involved in RAS-mediated apoptosis is the
Raf–ERK pathway.32–34 p53 is also thought to be involved in
RAS-mediated apoptosis, as RAS is no longer able to induce
apoptosis following p53 loss.34–36 RAS is known to stimulate
p53 activity through the induction of Arf and PML.37–39
However, under the conditions used in these studies, RAS
is likely to enhance the apoptotic function of p53 indepen-
dently of Arf, as UO2S and MCF7 cells do not express Arf.40
The overall effect of RAS on p53 activity may be dependent on
a balance between the different pathways linking the two
proteins.
The ability of oncogenes to stimulate cell cycle arrest or
apoptosis allows the cell to have a fail-proof system:
oncogene activation would, instead of inducing the cell to
proliferate in an uncontrolled manner, activate tumour-
suppressor proteins, thereby preventing the cell from replicat-
ing its damage. Although cell cycle arrest and apoptosis are
both efficient ways for cells to prevent propagation of their
damage, apoptosis is irreversible and therefore more
effective. The identification of ASPP1 and ASPP2 as
mediators of RAS and p53 in regulating apoptosis suggests
that oncogenic RAS would put pressure on p53 to induce
apoptosis. Therefore, the discovery that ASPP1 and ASPP2
cooperate with RAS to enhance p53-induced apoptosis
suggests that loss of ASPP1 or ASPP2 expression may be
a frequent event in human cancers with mutant RAS. This
finding may provide a novel molecular explanation for why
RAS and p53 mutations are so tightly associated in human
cancer.
Materials and Methods
Protein purification. Both recombinant RAS and the N-terminus of ASPP1
were purified from BL21 bacteria. Protein expression was induced by IPTG
(0.2 mM) for 3 h, and the cells were sonicated and then lysed. The lysate was spun
at 10 000 g and the supernatant recuperated. The recombinant proteins were
purified by Glutathionine Sepharose 4B beads (Pharmacia Biotech AB, Stockholm,
Sweden) as described by the manufacturer in the case of RAS or in the case of
N-terminus ASPP1 by nickel columns (Qiagen, West Sussex, UK). The GST tag of
RAS was cleaved off with bovine thrombin (Sigma, Dorset, UK) at a concentration
of 5 units/ml and the thrombin removed by P-aminobenzamidine-agarose beads
(Sigma, West Sussex, UK). The GST-tagged ASPP2 fragment (693–1128) was
purified by Glutathionine Sepharose 4B beads (Pharmacia Biotech AB). The
protein was concentrated and re-suspended in 1 kinase buffer (50 mM Tris-HCl,
pH 7.5, 270 mM sucrose, 0.1 mM EGTA and 0.1% mercaptoethanol).
RAS GDP/GTP loading. 2.5mg of recombinant protein purified from
Escherichia coli was incubated in a total volume of 320ml assay buffer containing
2mCi [3H] GDP or [3H] GTP in a water bath for 10 min at 30 1C. An aliquot of each
sample had its tritium content measured to check the equal loading of GDP and GTP.
Figure 5 RAS oncogene enhances the apoptotic function of p53 via ASPP1 and ASPP2. (a) ASPP1 and ASPP2 work with endogenous RAS to stimulate apoptosis.
shRNA against HRAS or KRAS was co-transfected with ASPP1 or ASPP2 in U2OS or MCF7 cells. FACS analysis was used to determine apoptotic cells. (b) Western blots
showing the expression levels of p53 and transfected ASPP1 and ASPP2. PCNA was used as a loading control. (c) Apoptotic activity is detected following oncogenic RAS
activation. HKe3 ER:HRASV12 cells were treated with 4-OHT (100 nM) for the indicated time. Western blot showing expression levels of cleaved PARP and ASPP2. (d) p53
depletion reduces oncogenic RAS-induced apoptosis. HKe3 ER:HRASV12 cells transfected with control siRNA or siRNA against p53 for 3 days were treated with or without
4-OHT (100 nM) for another day. Western blots showing expression levels of cleaved PARP and p53
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Reporter assay. Saos2 cells (7 105) were plated 24 h prior to transfection
in 6-cm-diameter dishes. All transactivation assays contained 1 mg of reporter
plasmid. Fifty nanograms of p53, 4 mg of ASPP2 or ASPP1 and 1.5mg of wild-type
or mutant HRAS expression plasmids were used as indicated. Cells were lysed in
reporter lysis buffer 16–24 h after transfection and assayed using the luciferase
assay kit (Promega, Madison, WI, USA). The fold increase of p53 and ASPP by
wild-type or mutant HRAS was determined by the activity of p53 and ASPP in
combination with wild-type or mutant HRAS divided by the activity of p53 and
ASPP alone.
Active RAS pull-down assay. Active RAS pull-down assay was performed
using the RBD of Raf-1–RBD, which were linked agarose (Millipore, Billerica,
MA, USA). HKe3 ER:HRASV12 cells were treated with or without OHT (100 nM)
for 2 days. Indicated cell lysates were incubated with 10 ml of a 50% slurry of
Raf-1–RBD agarose. Subsequent blotting was done with indicated antibodies.
In vivo immunoprecipitation. 1–4 mg of lysate was pre-cleared with
protein G beads for 30 min at 4 1C and subsequently incubated with antibody
prebound to protein G beads for 2–16 h at 4 1C. The beads were washed three
Figure 6 RAS activation induces ASPP2 translocation and enhances p53 binding in colon cancer cells. (a) RAS activation induces ASPP2 translocation.
Immunofluorescence staining of ASPP2 in HKe3 ER:HRASV12 cells treated without (control) or with 100 nM 4-OHT for 3 days. (b) RAS activation induces cytoplasmic and
nuclear accumulation of ASPP2. Cytoplasmic and nuclear fractions in HKe3 ER:HRASV12 cells with indicated treatments were isolated. GAPDH was used as a loading control
for the cytoplasmic fraction, whereas Lamin B was used as a loading control for the nuclear fraction. The levels of ASPP2 and p53 were calculated by densitometry. Fold
increase was calculated by normalising control group. (c) RAS activation enhances the binding between ASPP2 and p53. Total cell lysates from HKe3 ER:HRASV12 cells
treated with or without 4-OHT were immunoprecipitated with an anti-p53 antibody or control IgG as indicated. (d) ASPP2 depletion reduces oncogenic RAS-induced apoptosis.
HKe3 ER:HRASV12 cells transfected with control siRNA or siRNA against ASPP2 for 3 days were treated with or without 4-OHT (100 nM) for another day. Western blots
showing expression levels of cleaved PARP and ASPP2. (e) Diagram summarises the interactions between ASPP2 and RAS for their regulation and functions (details are
provided in Discussion)
ASPP1/2 in RAS signalling and apoptosis
Y Wang et al
533
Cell Death and Differentiation
times with NP40 buffer. Immunoprecipitations were analysed by western blots as
indicated.
Immunofluorescence. Cells were fixed in 4% PBS–paraformaldeyde for
15 min, incubated in 0.2% TritonX-100 for 5 min, then in 0.2% Fish Skin Gelatine in
PBS for 10 min and stained for 1 h with anti-RAS (RAS clone 10, Upstate Millipore
Corporate Headquarters) or anti-ASPP2 (DX54.10 for human or S32 for mouse).
Antibodies were used at 1 : 100 dilution in 0.2% Fish Skin Gelatine–PBS,
respectively. Staining with the secondary antibody and Hoechst was performed as
described before, followed by visualisation under a fluorescence microscope.
Flow cytometry. For FACS analysis, 106 cells were plated 24–48 h prior to
transfection in 10-cm-diameter plates. All cells were transfected with 2mg of a
plasmid expressing CD20 as a transfection marker, 10 mg ASPP1 or ASPP2, 9 mg
HRAS shRNA or KRAS shRNA as indicated. Both attached and floating cells were
harvested using 4 mM EDTA–PBS and stained with FITC-conjugated anti-CD20
antibody. The cells were then fixed and stained with propidium iodide. The DNA
content of all the cells expressing CD20 was analysed using a flow cytometer
(Becton Dickinson, San Jose, CA USA).
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